



09-21-00

RECEIVED

1616

Please type a plus sign (+) inside this box → ☒Approved for use through 09/30/2000. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TECH CENTER 1600/2337

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/609,552
	Filing Date	6/30/00
	First Named Inventor	MICHAEL F. MURRAY
	Group Art Unit	1616
	Examiner Name	Not Yet Known
Total Number of Pages in This Submission	Attorney Docket Number	16059-001

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input checked="" type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Additional Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Small Entity Statement	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Joseph R. Meaney Mohr, Hackett, Pederson, Blakley & Randolph, P.C.
Signature	
Date	9/20/2000

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: 9/20/2000			
Typed or printed name	Karol J. Cannizzaro		
Signature		Date	9/20/00

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


Under the Paperwork Reduction Act of 1995,

Complete if Known

Application Number	09/609,552
Filing Date	6/30/00
First Named Inventor	MURRAY
Group Art Unit	1616
Examiner Name	Not Yet Known
Attorney Docket Number	16059-001

(use as many sheets as necessary)

Sheet 1 of 1

[illegible][illegible]Date
Considered

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

+

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

2

Attorney Docket Number

16059-001

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
-----------------------	--------------------------	---

b


TANG ALICE M., et al., Dietary Micronutrient Intake and Risk of Progression to Acquired Immunodeficiency Syndrome (AIDS) in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Homosexual Men, *Amer. J. of Epidem.*, Vol. 138, no. 11, 932-951 (1993).

△

TANG ALICE M., GRAHAM NEIL MH, SAAH ALFRED J., Effects of Micronutrient Intake on Survival in Human Immunodeficiency Virus Type 1 Infection, *Amer. J. of Epidem.*, Vol. 143, no. 12, 1244-1256 (1996).

✓

KRASILNIKOV NN, et al., Inhibitors of ADP-Ribosylation as Antiviral Drugs: Experimental Study on the Model of HIV Infection (1990).



**Exami
ner
Signat
ure**

Date Considered


7/23/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a checkmark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box 


PTO/SB/08B (10/96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark office. U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1400 PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/609,552
		Filing Date	6/30/00
		First Named Inventor	MICHAEL F. MURRAY
		Group Art Unit	1616
		Examiner Name	Not Yet Known
Sheet 1	of 2	Attorney Docket Number	16059-001

OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		PETLEY A., et al., The Pharmacokinetics of Nicotinamide in Humans and Rodents, Diabetes, 44:152-155 (1995).	
		DIPALMA JR., THAYER WS, Use of Niacin as a Drug, Ann. Rev. Nutr. 11:169-187 (1991).	
B		GISSLEN M., LARSON M., NORKRANS F., FUCHS D., WACHTER H., HAGBERG L., Tryptophan Concentrations Increase in Cerebrospinal Fluid and Blood After Zidovudine Treatment in Patients with HIV Type I Infection, AIDS Research and Human Retroviruses, 10(8): 947-951 (1994).	
O		RR BROWN, et al., Implications of Interferon Induced Tryptophan Catabolism in Cancer, Autoimmune Disease and AIDS, Kynurone and Serotin Pathways, 425-435 (1991)	
B		MURRAY MF, NGHIEM M., SRINIVASAN A., HIV Infection Decreases Intracellular Nicotinamide Adenine Dinucleotide [NAD], Biochemical and Biophysical Research Communications, 212:126-131 (1995)	
B		MURRAY MF, SRINIVASAN A., Nicotinamide Inhibits HIV-1 in Both Acute and Chronic In Vitro Infection, Biochemical and Biophysical Research Communications, (3), 210:954-959 (1995).	
B		SKURNICK JH, et al., Micronutrient Profiles in HIV-1 Infected Heterosexual Adults, J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol, 12(1):75-83, (1996).	
B		MURRAY MF, Niacin as a Potential AIDS Preventive Factor, Medical Hypotheses, 53(5):375-379 (1999),	
M		SAVARINO A., et al., Apoptotic DNA Fragmentation, and its In Vitro Prevention by Nicotinamide, in Lymphocytes from HIV-1 Seropositive Patients and in HIV-1-Infected MT-4 Cells, Cell Biochem. And Funct., Vol. 15:171-179 (1997).	
D		SAVARINO A., et al., Investigation of the Potential Role of Membrane CD38 in Protection Against Cell Death Induced by HIV-1, J. Biolog. And Homeostat. Agents, Vol. 10, no. 1, pp. 13-18 (1996).	

Examiner Signature		Date Considered	7/25/07
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a checkmark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.